JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $179 from $171 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences’ Earnings Call Highlights Robust Growth
- Neurocrine Biosciences Completes Phase 2 Study on NBI-1070770 for Depression
- Neurocrine price target raised to $184 from $170 at Needham
- Neurocrine falls after DOJ sends Ingrezza investigative demand
- Neurocrine pullback despite ‘big quarter’ a buying opportunity, says RBC Capital